Credit Suisse upgraded Esperion Therapeutics to Neutral from Underperform with a price target of $7, up from $6.50. The analyst sees more limited downside risk following release of the full CLEAR Outcomes trial dataset. The CLEAR data represented the "last hard catalyst" for Esperion until the anticipated bempedoic acid label change and related Daiichi milestone in the first half of 2024, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ESPR:
- Esperion Tanks on Nexletol Cardiovascular Data
- Esperion to hold a conference call
- Esperion announced full results from landmark CLEAR outcomes study
- Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
- Esperion reinstated with a Neutral at BofA